McDermott Will & Schulte has advised Deep Track Capital. Hemab Therapeutics, a clinical-stage biotechnology company specializing in the development of novel prophylactic therapeutics for underserved bleeding...
Deep Track Capital Invests in Hemab Therapeutics’ $157 Million Series C Financing
TORL BioTherapeutics’ $158 Million Series B-2 Financing
Schulte Roth & Zabel represented Deep Track Capital, while Crandon Law represented TORL BioTherapeutics in the transaction. TORL BioTherapeutics announced its closing of an oversubscribed $158 million Series...


























